China Pharma Holdings, Inc.CPHI
Price (close)
$0.75
Market cap
$32.3M
P/E
—
Revenue (TTM)
$3.9M
Net income
-$4.5M
Dividend yield
—
1-year total return
-61.5%
Net margin
-114.3%
Revenue growth
-11.0%
Debt / equity
0.05x
What China Pharma Holdings, Inc. does.
company. China Pharma is not a Chinese operating company and all the operations are conducted by our wholly owned subsidiary, Hainan Helpson
Medical and Biotechnology Co., Ltd. (“Helpson”) and Helpson’s subsidiaries in China. We, through Helpson, are principally
engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $10.9M | $9.6M | $8.1M | $7.0M | $4.5M | $4.1M |
| Net income | -$2.9M | -$3.4M | -$4.0M | -$3.1M | -$4.7M | -$3.2M |
| Free cash flow | -$909,567 | -$687,893 | -$811,509 | -$711,203 | -$444,474 | $88,937 |
More on CPHI.
- China Pharma Holdings, Inc. summary
- China Pharma Holdings, Inc. financial statements
- China Pharma Holdings, Inc. key metrics
- China Pharma Holdings, Inc. health scores and style box
- China Pharma Holdings, Inc. earnings
- China Pharma Holdings, Inc. dividends
- China Pharma Holdings, Inc. valuation
- China Pharma Holdings, Inc. ownership and insiders
- China Pharma Holdings, Inc. peers
Figures from China Pharma Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.